Phenotypic Screening AI Market to Hit $13.51 Billion by 2035 From $1.19 Billion
Updated
Updated · Market.us · Jun 9
Phenotypic Screening AI Market to Hit $13.51 Billion by 2035 From $1.19 Billion
1 articles · Updated · Market.us · Jun 9
Summary
The market is projected to expand at a 27.5% CAGR from 2025 to 2035 as drugmakers adopt AI tools to speed phenotypic screening and cut early-stage development failures.
About 70% of drug projects fail because of weak early testing, while high-content screening can generate terabytes of cell-image data in a single run, making AI increasingly central to analysis.
North America led the market in 2025 with a 40.3% share and $0.47 billion in revenue; the U.S. alone was valued at $0.43 billion.
Machine learning and deep learning held a 70.5% technology share in 2025, while drug discovery accounted for 51.4% of applications and pharma-biotech companies made up 65.7% of end users.
Generative AI and cloud-based platforms are widening adoption by creating virtual cell images, improving early hit rates, and helping labs reduce screening costs by 30% to 50%.